＜業績＞
Han M, Yamaguchi S, Onishi M, Fujii T, Hosoya M, Wen X, Kido H, Kato S. The MDM2 and CDKN2A Copy-number-variation Influence the TP53-signature-score in Wild-type TP53 Luminal Type Breast Cancer. Anticancer Res. 2022 May;42(5):2277-2288. doi: 10.21873/anticanres.15707.
PMID: 35489754.
Suzuki K, Igata H, Abe M, Yamamoto Y, small RNA based cancer classification project. Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities Cancer Sci. 2022 Jun;113(6):2144-2166. doi: 10.1111/cas.15309.
Epub 2022 Mar 14. PMID: 35218669.
Kido H, Kato S, Funahashi K, Shibuya K, Sasaki Y, Urita Y, Hori M, Mizumura S. The metabolic parameters based on volume in PET/CT are associated with clinicopathological N stage of colorectal cancer and can predict prognosis. EJNMMI Res. 2021 Sep 6;11(1):87.
doi: 10.1186/s13550-021-00831-5. PMID: 34487264; PMCID: PMC8421476.
Funato M, Tsunematsu Y, Yamazaki F, Tamura C, Kumamoto T, Takagi M, Kato S, Sugimura H, Tamura K. Characteristics of Li-Fraumeni Syndrome in Japan; A Review Study by the Special Committee of JSHT. Cancer Sci. 2021 May 1;112(7):2821-34. doi: 10.1111/cas.14919.
Epub ahead of print. PMID: 33932062; PMCID: PMC8253286.
Nakano S, Imawari Y, Mibu A, Kato S, Yamaguchi S, Otsuka M, Sano M. Molecular Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer in Clinical Practice. J Nippon Med Sch. 2022 Mar 11;89(1):88-94.
doi: 10.1272/jnms.JNMS.2022_89-203. Epub 2021 Apr 19. PMID: 33867426.
Yamashiro Y, Kurihara T, Hayashi T, Suehara Y, Yao T, Kato S, Saito T. NTRK fusion in Japanese colorectal adenocarcinomas. Sci Rep. 2021 Mar 11;11(1):5635. doi: 10.1038/s41598-021-85075-y. PMID: 33707574; PMCID: PMC7952565.
Kato S. Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer. Diagnostics (Basel). 2021 Feb 6;11(2):252. doi: 10.3390/diagnostics11020252. PMID: 33562094; PMCID: PMC7914923.
Suehara Y, Kohsaka S, Yamaguchi S, Hayashi T, Kurihara T, Sano K, Sasa K, Akaike K, Ueno T, Kojima S, Ikegami M, Mizuno S, Okubo T, Kim Y, Kaneko K, Saito T, Kato S, Mano H. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an
Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas. Clin Orthop Relat Res. 2020 Nov;478(11):2461-2476. doi: 10.1097/CORR.0000000000001322. PMID: 32567826; PMCID:
PMC7594915.
Suehara Y, Hayashi T, Saito T, Kato S, Ladanyi M. [Ⅱ.MSK-IMPACT of Bone and Soft Tissue Sarcomas in Japan]. Gan To Kagaku Ryoho. 2020 Mar;47(3):428-435. Japanese. PMID: 32381909.
Takakuwa K, Mogushi K, Han M, Fujii T, Hosoya M, Yamanami A, Akita T, Yamashita C, Hayashida T, Kato S, Yamaguchi S. A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma.
Sci Rep. 2020 Apr 10;10(1):6214. doi: 10.1038/s41598-020-63200-7. PMID: 32277151; PMCID: PMC7148318.
Naito Y, Mishima S, Akagi K, Igarashi A, Ikeda M, Okano S, Kato S, Takano T, Tsuchihara K, Terashima K, Nishihara H, Nishiyama H, Hiyama E, Hirasawa A, Hosoi H, Maeda O, Yatabe Y, Okamoto W, Ono S, Kajiyama H, Nagashima F, Hatanaka Y, Miyachi M, Kodera
Y, Yoshino T, Taniguchi H. Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor
tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol. 2020 Mar;25(3):403-417. doi: 10.1007/s10147-019-01610-y. Epub 2020 Jan 24. PMID: 31974683; PMCID: PMC7046581.
Kato S, Fujimura J, Nozaki Y, Yamaguchi S, Takagi T, Hayashi T, Saito T, Henry D, Ku N, Suehara Y. [A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System]. Gan To Kagaku
Ryoho. 2019 Oct;46(10):1595-1597. Japanese. PMID: 31631147.
Nozaki Y, Yamaguchi S, Takagi T, Kato S. [An Effective Treatment of Relapsed Leiomyosarcoma with Fourth-Line Trabectedin]. Gan To Kagaku Ryoho. 2019 Feb;46(2):275-277. Japanese. PMID: 30914533.
Kato S, Hayashi T, Suehara Y, Hamanoue H, Yamanaka S, Ichikawa Y, Higurashi T, Ohashi K, Yamaguchi S, Nozaki Y, Terao Y, Saito T. Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. Jpn
J Clin Oncol. 2019 Feb 1;49(2):174-182. doi: 10.1093/jjco/hyy173. PMID: 30541038.
Watanabe J, Togo S, Sumiyoshi I, Namba Y, Suina K, Mizuno T, Kadoya K, Motomura H, Iwai M, Nagaoka T, Sasaki S, Hayashi T, Uekusa T, Abe K, Urata Y, Sakurai F, Mizuguchi H, Kato S, Takahashi K. Clinical features of squamous cell lung cancer with anaplastic
lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review. Oncotarget. 2018 May 8;9(35):24000-24013. doi: 10.18632/oncotarget.25257. PMID: 29844868; PMCID: PMC5963613.
Yamaguchi S, Takahashi S, Mogushi K, Izumi Y, Nozaki Y, Nomizu T, Kakugawa Y, Ishida T, Ohuchi N, Ishioka C, Kato S. Molecular and clinical features of the <i>TP53</i> signature gene expression profile in early-stage breast cancer. Oncotarget.
2018 Feb 8;9(18):14193-14206. doi: 10.18632/oncotarget.24447. PMID: 29581837; PMCID: PMC5865663.
Yamaguchi S, Fujii T, Izumi Y, Fukumura Y, Han M, Yamaguchi H, Akita T, Yamashita C, Kato S, Sekiya T. Identification and characterization of a novel <i>adenomatous polyposis coli</i> mutation in adult pancreatoblastoma. Oncotarget. 2018 Jan
6;9(12):10818-10827. doi: 10.18632/oncotarget.24017. PMID: 29535845; PMCID: PMC5828192.
